RL-007: First patient dosed in the Phase 2b study of RL-007 in Cognitive Impairment Associated with Schizophrenia.GRX-917: Presented PD data from the completed Phase 1 study, which suggest the. | May 11, 2023
RL-007: First patient dosed in the Phase 2b study of RL-007 in Cognitive Impairment Associated with Schizophrenia.GRX-917: Presented PD data from the completed Phase 1 study, which suggest the potential
Investegate announcements from atai Life Sciences, atai Life Sciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Pipeline Highlights
atai Life Sciences (ATAI) Reports Q4, Provides Clinical Pipeline Highlights streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
atai's development candidates, such as RL-007 and GRX-917, all represent significant opportunities to address unmet medical needs of patients living with mental health conditionsContinued operational progress